Groowe Groowe / Newsroom / LLY
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

LLY News

Eli Lilly & Co.

The Skin of Color Society (SOCS) Reports an Impactful Year of Progress, Expansion, and Innovation Toward Advancing Knowledge and Excellence in Patient Care

prnewswire.com
JNJ LLY SNY REGN ABBV AERO BIIB GALT TAK ELMD PFE SUN INCY BMY ARQT UCB

Debbie's Dream Foundation: Curing Stomach Cancer Thanks Its 2025 Industry Partners for Advancing Critical Programs and Patient Support

prnewswire.com
AMGN BMY ARCX AZN GILD JAZZ LLY MRK ASTL THTX

Best Zepbound Alternative for 2026? FDA Regulatory Timeline Reshapes Telehealth Tirzepatide Access as SkinnyRx Platform Lists Compounded Options

globenewswire.com
LLY

Ozempatch: Do Herbal Weight Loss Patches Actually Work? 2026 Consumer Analysis as GLP-1 Patch Ads Surge During Resolution Season

globenewswire.com
NVO LLY

Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways

globenewswire.com
NVO LLY

Capital Square Launches New Active Living DST Offering in Richmond's Short Pump Submarket

prnewswire.com
LLY

Best Peptides for Weight Loss 2026: Industry Analysis Examines Compounded GLP-1 Telehealth Access and Pricing Transparency

globenewswire.com
NVO LLY

GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: Growing Shift of Weekly Injectables Toward Orals and Multi-Agonists - ResearchAndMarkets.com

businesswire.com
LLY NVO

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly USA - English USA - English APAC - English

prnewswire.com
LLY

Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies

prnewswire.com
LLY